Jul 22, 2026The introduction of betting markets on drug trial results—reminiscent of sports betting—opens sweeping ethical, regulatory, and scientific questions. While claimants suggest that such markets could yield insights about the future of medicine, healthcare leaders are voicing grave concerns about transparency, data integrity, and insider trading risks. This article offers a comprehensive, analytical look at what's at stake.
Jonathan Blake
Jul 21, 2026As Trump administration policies targeting drug pricing roll out, rare disease drug manufacturers are pushing back against federal price cut initiatives. The lobbying efforts reflect broader tensions between price regulation, pharmaceutical innovation, and treatment access for vulnerable populations.
Jonathan Blake 
Jul 21, 2026A closer examination of the FDA’s 505(b)(2) pathway reveals a regulatory mechanism that can accelerate innovation, reduce costs, and extend product lifecycles for the pharmaceutical industry. Yet, the potential of this approach is often underestimated, prompting experts to call for a renewed strategic focus from both established and emerging biopharma firms.
Dr. Alex Morgan
Jul 20, 2026As the FDA embarks on a radical policy shift toward publishing drug rejections, the agency finds itself at the crossroads of transparency and legal ambiguity. Stakeholders warn of inadequate public debate and the risk of undermining regulatory norms as the debate intensifies.
Dr. Priya Nandakumar
Jul 19, 2026The increasing occurrence of hazardous wildfire smoke events in the U.S. and Canada has forced policy makers, scientists, and health officials to revisit the regulatory playbook. By reflecting on the history of smog regulation in the twentieth century, this post examines the potential pathways and pitfalls for addressing present-day challenges in air quality management.
Daniel Cho
Jul 19, 2026A recent letter from the FDA’s acting director to Congressional leadership clarifies that certain peer-reviewed papers do not reflect agency policy or its interpretation of regulatory issues. The move comes amid lawmaker criticism about potential overreach and confusion in health policy debates.
Daniel Cho 
Jul 19, 2026The push for annual testosterone screenings in the military is presented as a public health and readiness initiative, but experts warn that such a move could introduce a host of unexpected clinical and social complications. This article explores the multifaceted debate, examining the science, policy aims, and unintended consequences that could emerge from widespread hormone screening.
Daniel Cho 
Jul 17, 2026Medicare is considering a notable policy shift that could incentivize clinicians to integrate more intensive counseling for smoking and alcohol cessation into routine patient care. With a 19% increase in reimbursement for those offering counseling, the change has the potential to address persistent challenges in preventing tobacco and alcohol-related illnesses.
Emily Carter
Jul 17, 2026An outbreak of the parasite cyclospora, leading to gastrointestinal illnesses across five states, has been definitively linked to lettuce sourced from Mexico and served at Taco Bell locations. The incident amplifies calls for stricter produce regulations and improved multinational food safety systems.
Sophia Reynolds
Jul 17, 2026Testosterone therapy remains a complex subject in U.S. healthcare, with access determined by a web of guidelines, eligibility criteria, and divergent provider and policy approaches. The issue is under active discussion amid broader debates about hormone medication as well as associated public health risks, including environmental stressors such as wildfire smoke and evolving approaches for rare disease treatment.
Jonathan Blake 
Jul 17, 2026With the 2027 Physician Fee Schedule, the Centers for Medicare and Medicaid Services (CMS) proposes major restrictions on remote patient monitoring (RPM) in response to reports of widespread abuse. This analysis dives into the motivations, possible ripple effects, and the broader context surrounding CMS’s controversial move, as well as its impact on digital health innovation, patient engagement, and chronic disease care.
Daniel Cho 
Jul 17, 2026The House Ways and Means Committee has unanimously advanced a bill set to significantly reform Medicare Advantage prior authorization. The move, commended by numerous healthcare stakeholders, signals a shift in how federal legislators and agencies balance access to care and fraud prevention. This in-depth analysis explores the possible impact of such reform on Medicare Advantage providers, patients, healthcare infrastructure, and the broader US healthcare policy landscape.
Sophia Reynolds 